Kymera Therapeutics Toekomstige groei
Future criteriumcontroles 1/6
De winst van Kymera Therapeutics zal naar verwachting dalen met 10% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 16.2% per jaar. De winst per aandeel zal naar verwachting dalen met 5.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -98.5% zijn.
Belangrijke informatie
-10.0%
Groei van de winst
-5.4%
Groei van de winst per aandeel
Biotechs winstgroei | 28.4% |
Inkomstengroei | 16.2% |
Toekomstig rendement op eigen vermogen | -98.5% |
Dekking van analisten | Good |
Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Recent updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 53 | -300 | -216 | -256 | 16 |
12/31/2025 | 64 | -265 | -225 | -180 | 19 |
12/31/2024 | 55 | -210 | -221 | -170 | 18 |
9/30/2024 | 88 | -167 | -148 | -125 | N/A |
6/30/2024 | 89 | -158 | -138 | -106 | N/A |
3/31/2024 | 79 | -155 | -136 | -98 | N/A |
12/31/2023 | 79 | -147 | -137 | -103 | N/A |
9/30/2023 | 47 | -167 | -174 | -150 | N/A |
6/30/2023 | 52 | -158 | -169 | -153 | N/A |
3/31/2023 | 47 | -159 | -163 | -157 | N/A |
12/31/2022 | 47 | -155 | -156 | -153 | N/A |
9/30/2022 | 46 | -154 | -155 | -152 | N/A |
6/30/2022 | 57 | -139 | -157 | -155 | N/A |
3/31/2022 | 64 | -124 | -148 | -146 | N/A |
12/31/2021 | 73 | -100 | -131 | -129 | N/A |
9/30/2021 | 70 | -79 | -113 | -111 | N/A |
6/30/2021 | 65 | -58 | 54 | 58 | N/A |
3/31/2021 | 49 | -48 | 69 | 77 | N/A |
12/31/2020 | 34 | -55 | 79 | 88 | N/A |
9/30/2020 | 23 | -53 | 90 | 97 | N/A |
6/30/2020 | 9 | -57 | -52 | -47 | N/A |
3/31/2020 | 6 | -52 | -17 | -15 | N/A |
12/31/2019 | 3 | -41 | 17 | 18 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat KYMR de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van KYMR ( 16.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van KYMR ( 16.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat KYMR binnen 3 jaar verliesgevend zal zijn.